First-Line Treatment for Premenstrual Dysphoric Disorder
Selective serotonin reuptake inhibitors (SSRIs) are the recommended first-line pharmacological treatment for premenstrual dysphoric disorder, with fluoxetine (10-20 mg/day), sertraline (50-150 mg/day), or paroxetine controlled-release (12.5-25 mg/day) being FDA-approved options that can be administered either continuously or during the luteal phase only. 1, 2
Treatment Algorithm
Step 1: Confirm Diagnosis with Prospective Tracking
Before initiating treatment, require prospective daily symptom tracking across at least two menstrual cycles to confirm that symptoms are truly luteal-phase specific and cause clinically significant impairment 3. This distinguishes PMDD from premenstrual exacerbation of underlying mood disorders.
Step 2: Initiate SSRI Therapy
Medication Selection:
- Fluoxetine: 10-20 mg/day (FDA-approved for PMDD) 1, 2
- Sertraline: 50-150 mg/day (FDA-approved for PMDD) 2, 4
- Paroxetine CR: 12.5-25 mg/day (FDA-approved for PMDD) 1, 2
- Escitalopram: 10-20 mg/day (effective but not FDA-approved for PMDD) 2
Dosing Strategy: You have two evidence-based options 4:
Luteal phase dosing: Administer for the last 2 weeks of the menstrual cycle only
- Reduces medication exposure and costs
- Equally effective as continuous dosing for most patients
- No discontinuation symptoms reported with this intermittent regimen
- Preferred if patient wants minimal medication exposure
Continuous dosing: Daily administration throughout the cycle
- May be preferred if patient has comorbid depression or anxiety
- Simpler adherence for some patients
Both regimens show similar efficacy, so choose based on patient preference and comorbid conditions 4.
Step 3: If SSRIs Fail or Are Not Tolerated
Important caveat: Approximately 40% of women with PMDD do not respond adequately to SSRIs 5. When accounting for placebo response, the actual response rate to SSRIs is often less than 60% 5.
Second-line options:
Combined oral contraceptive with drospirenone: Drospirenone 3 mg + ethinyl estradiol 20 mcg in a 24/4 regimen (24 days active pills, 4 days inactive) 2, 6
- Most effective COC formulation for PMDD
- Particularly effective for both physical and emotional symptoms
- Consider as first-line if patient also needs contraception
Other psychotropic agents 7, 8:
- Venlafaxine (SNRI)
- Duloxetine (SNRI)
- Buspirone (modest efficacy, fewer sexual side effects than SSRIs)
- Alprazolam (modest efficacy, risk of dependence limits use)
Step 4: Adjunctive and Supportive Measures
Calcium supplementation: 1200 mg/day is the only supplement with consistent evidence of therapeutic benefit 7
Cognitive behavioral therapy (CBT): Reduces functional impairment, depressed mood, anxiety, mood swings, irritability, and symptom severity 2, 3. Can be used as monotherapy for mild-to-moderate symptoms or combined with pharmacotherapy.
Critical Clinical Considerations
Black box warning: Both fluoxetine and paroxetine carry warnings for treatment-emergent suicidality, particularly in adolescents and young adults 1. Monitor closely during treatment initiation.
Pharmacogenetic considerations: Both fluoxetine and paroxetine are metabolized through CYP2D6, which shows genetic variation 1. In CYP2D6 poor metabolizers, these medications may accumulate to higher levels, potentially increasing side effects.
Common pitfall: Do not use progesterone for PMDD treatment—it has consistently failed to show efficacy in large randomized controlled trials 4.
Avoid misdiagnosis: Distinguish PMDD from premenstrual exacerbation (PME) of underlying mood disorders, which affects 50-60% of individuals with mood disorders and requires different treatment approaches 3.
Sexual dysfunction: SSRIs commonly cause sexual side effects including difficulty reaching orgasm and hypoactive sexual desire disorder 9. If this occurs, consider switching to buspirone or a COC, or adding bupropion.
Treatment Response Timeline
SSRIs work more rapidly in PMDD than in depression—symptom improvement often begins within the first cycle of treatment 4. If no response after 2-3 cycles at adequate doses, switch to an alternative SSRI or consider second-line options.
Do not measure FSH levels to guide treatment—they are not useful for monitoring PMDD therapy 10.